The estimated Net Worth of William H Rastetter is at least $8.88 Milione dollars as of 15 August 2024. William Rastetter owns over 14,250 units of Neurocrine Biosciences stock worth over $4,554,032 and over the last 21 years he sold NBIX stock worth over $3,650,182. In addition, he makes $671,980 as Independent Chairman of the Board at Neurocrine Biosciences.
Sign up
William Rastetter NBIX stock SEC Form 4 insiders trading
William has made over 28 trades of the Neurocrine Biosciences stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 14,250 units of NBIX stock worth $2,090,333 on 15 August 2024.
The largest trade he's ever made was exercising 580,222 units of Neurocrine Biosciences stock on 4 May 2004 worth over $678,860. On average, William trades about 18,944 units every 65 days since 2003. As of 15 August 2024 he still owns at least 37,491 units of Neurocrine Biosciences stock.
You can see the complete history of William Rastetter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Rastetter biography
Dr. William H. Rastetter Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Rastetter has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. Currently, he serves as the Chairman of the Board of Directors for Fate Therapeutics, a publicly traded company focused on cellular therapies, as well as for Daré Bioscience, Inc. (previously known as Cerulean Pharma Inc.), a publicly traded company focused on women’s health care. Dr. Rastetter also serves on the Board of Directors for Regulus Therapeutics Inc., a publicly traded company focused on RNA based therapeutics, and Grail, Inc., a private company developing deep sequencing approaches for disease diagnosis, with an initial focus on the early diagnosis of cancer. Dr. Rastetter serves as an advisor to SVB Leerink and Illumina Ventures. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013 and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. Earlier, he served as Chairman and Chief Executive Officer of IDEC Pharmaceuticals Corporation until its merger with Biogen in 2003; he joined IDEC Corporation as its Chief Executive Officer at the company’s founding in 1986. From 1984 to 1986, Dr. Rastetter was Director of Corporate Ventures at Genentech, where from 1982 to 1984 he held scientific positions. He held a series of faculty positions including Associate Professor at the Massachusetts Institute of Technology (“MIT”) from 1975 to 1982. Dr. Rastetter has a Bachelor of Science degree in chemistry from MIT and received Master of Art and doctorate degrees in chemistry from Harvard University.
What is the salary of William Rastetter?
As the Independent Chairman of the Board of Neurocrine Biosciences, the total compensation of William Rastetter at Neurocrine Biosciences is $671,980. There are 13 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
How old is William Rastetter?
William Rastetter is 72, he's been the Independent Chairman of the Board of Neurocrine Biosciences since 2011. There are no older and 24 younger executives at Neurocrine Biosciences.
What's William Rastetter's mailing address?
William's mailing address filed with the SEC is 12780 EL CAMINO REAL, , SAN DIEGO, CA, 92130.
Insiders trading at Neurocrine Biosciences
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
What does Neurocrine Biosciences do?
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
What does Neurocrine Biosciences's logo look like?
Complete history of William Rastetter stock trades at Biogen Inc, Fate Therapeutics Inc, Illumina Inc, Neurocrine Biosciences, Regulus Therapeutics Inc e Dare Bioscience Inc
Neurocrine Biosciences executives and stock owners
Neurocrine Biosciences executives and other stock owners filed with the SEC include:
-
Kevin Gorman,
Chief Executive Officer, Director -
Matthew Abernethy,
Chief Financial Officer -
Eric Benevich,
Chief Commercial Officer -
Eiry Roberts,
Chief Medical Officer -
Haig Bozigian,
Chief Development Officer -
Kyle Gano,
Chief Business Development and Strategy Officer -
Dimitri Grigoriadis,
Chief Research Officer -
Dr. Kevin C. Gorman Ph.D.,
CEO & Director -
Dr. Eiry Wyn Roberts,
Chief Medical Officer -
Leslie Norwalk,
Independent Director -
Matthew C. Abernethy,
Chief Financial Officer -
Eric S. Benevich,
Chief Commercial Officer -
Kyle W. Gano,
Chief Bus. Devel. and Strategy Officer -
William Rastetter,
Independent Chairman of the Board -
Stephen Sherwin,
Independent Director -
Richard Pops,
Independent Director -
George Morrow,
Independent Director -
Gary Lyons,
Independent Director -
Todd Tushla,
Investor Relations -
Julie Cooke,
Chief Human Resource Officer -
Shalini Sharp,
Independent Director -
Darin Lippoldt,
Chief Legal Officer and Corporate Secretary -
Malcolm Lloyd-Smith,
Chief Regulatory Officer -
David Boyer,
Chief Corporate Affairs Officer -
Julie S. Cooke,
Chief HR Officer -
Darin M. Lippoldt,
Chief Legal Officer & Corp. Sec. -
Jane Sorensen,
Head of Investor Relations -
Dr. Jude Onyia Ph.D.,
Chief Scientific Officer -
Dr. Dimitri E. Grigoriadis,
Chief Research Officer -
Matt Abernethy,
Chief Financial Officer -
Corinne H Nevinny,
Director -
Christopher Flint O Brien,
Sr. VP & Chief Medical Officer -
Joseph A Mollica,
Director -
David Alexandre C Gros,
President & COO -
Alfred Sandrock,
Director -
Christine A Poon,
Director -
Wylie W Vale,
Director -
Timothy Coughlin,
VP and Chief Financial Officer -
Jensen Margaret E Valeur,
Senior VP and General Counsel -
Partners L P/Ilbiotechnolog...,
-
Johanna Mercier,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Henry Pan,
Executive VP and CMO -
Wendall Wierenga,
EVP, Research & Development -
Richard J Ranieri,
Sr. VP, Human Resources -
Thomas Mitchell W,
Director -
Ingrid Delaet,
Chief Regulatory Officer -
Paul W Hawran,
Executive VP and CFO -
Paul J Conlon,
Vice President Research (Biol) -
Lawrence Steinman,
Director -
John Saunders,
Vice President Research (Chem) -
Robert J Little,
SVP, Commercial Operations -
D Bruce Campbell,
Senior Vice President -
Jude Onyia,
Chief Scientific Officer